- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03234907
Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease.
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Examine the Efficacy and Safety of Intravenous Vedolizumab (300 mg) Infusion Treatment in Chinese Subjects With Moderately to Severely Active Crohn's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The drug being tested in this study is called vedolizumab. Vedolizumab will be administered as an intravenous (IV) infusion in Chinese participants. This study will investigate the efficacy and safety of vedolizumab IV as induction and maintenance therapy in participants with moderately to severely active Crohn's Disease (CD).
The study will enroll approximately 300 moderately to severely active Chinese patients with CD.
Induction Phase: participants will be randomized 2:1 to receive:
- Vedolizumab IV 300 mg
- Placebo IV
Participants will receive vedolizumab 300 mg or matching placebo, intravenous (IV) infusion at Weeks 0, 2, and 6 in the induction phase. At Week 10, participants will be assessed for clinical response. Results of Week 10 clinical response will determine the treatment pathway in the maintenance phase.
Maintenance Phase: participants who achieved clinical response at Week 10 will continue to receive the same treatment as they received in Induction Phase; every 8 weeks (Q8W) starting at Week 14. Participants who received vedolizumab IV or placebo in the Induction Phase and did not achieve clinical response at Week 10 will receive vedolizumab every 4 weeks (Q4W) starting at Week 14.
This multi-center trial will be conducted in China. The overall time to participate in this study is 60 weeks. Participants will make multiple visits to the clinic, and will be contacted by telephone, 6 months after last dose of study drug for a long-term follow-up safety survey.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Anhui
-
Hefei, Anhui, China, 230024
- Gastroenterology
-
-
Beijing
-
Beijing, Beijing, China, 100050
- Gastroenterology
-
Beijing, Beijing, China, 100730
- Gastroenterology
-
-
Chongqing
-
Chongqing, Chongqing, China, 400037
- Gastroenterology
-
-
Fujian
-
Fuzhou, Fujian, China, 350025
- Gastroenterology
-
Xiamen, Fujian, China, 361004
- Gastroenterology
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- Gastroenterology
-
Guangzhou, Guangdong, China, 510515
- Gastroenterology
-
Guangzhou, Guangdong, China, 510655
- Gastroenterology
-
-
Hubei
-
Wuhan, Hubei, China, 430000
- Gastroenterology
-
Wuhan, Hubei, China, 430030
- Gastroenterology
-
Wuhan, Hubei, China, 430060
- Gastroenterology
-
-
Hunan
-
Changsha, Hunan, China, 410008
- Gastroenterology
-
Changsha, Hunan, China, 410011
- Gastroenterology
-
Changsha, Hunan, China, 410013
- Gastroenterology
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Gastroenterology
-
Nanjing, Jiangsu, China, 210029
- Gastroenterology
-
Wuxi, Jiangsu, China, 241023
- Gastroenterology
-
-
Jiangxi
-
Nanchang, Jiangxi, China, 330006
- Gastroenterology
-
-
Jilin
-
Changchun, Jilin, China, 130000
- Gastroenterology
-
-
Liaoning
-
Shenyang, Liaoning, China, 110022
- Gastroenterology
-
-
Shanghai
-
Shanghai, Shanghai, China, 200025
- Gastroenterology
-
Shanghai, Shanghai, China, 200032
- Gastroenterology
-
Shanghai, Shanghai, China, 200072
- Gastroenterology
-
Shanghai, Shanghai, China, 200092
- Gastroenterology
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Gastroenterology
-
-
Yunnan
-
Kunming, Yunnan, China, 650032
- Gastroenterology
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310009
- Gastroenterology
-
Hangzhou, Zhejiang, China, 310016
- Gastroenterology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Has a diagnosis of Crohn's disease (CD) established at least 3 months prior to Screening by clinical and endoscopic evidence corroborated by a histopathology report. Cases of CD established at least 6 months prior to randomization for which a histopathology report is not available will be considered based on the weight of evidence supporting the diagnosis and excluding other potential diagnosis, and must be discussed with the sponsor on a case-by-case basis prior to randomization.
Has moderately to severely active CD as determined by a Crohn's Disease Activity Index (CDAI) score of 220 to 400 within 7 days prior to the first dose of study drug and 1 of the following:
- C-reactive protein (CRP) level >2.87 mg/L during the Screening Phase, OR
- Ileocolonoscopy with photographic documentation of a minimum of 3 nonanastomotic ulcerations (each >0.5 cm in diameter) or 10 aphtous ulcerations (involving a minimum of 10 contiguous cm of intestine) consistent with CD, within 4 months prior to randomization, OR
- Fecal calprotectin >250 μg/g stool during the Screening Phase in conjunction with computed tomography enterography (CTE), magnetic resonance enterography (MRE), contrast enhanced small bowel radiography, or wireless capsule endoscopy revealing CD ulcerations (aphthae not sufficient), within 4 months prior to Screening
- Has CD involvement of the ileum and/or colon, at a minimum.
- Has extensive colitis or pancolitis of >8 years duration or limited colitis of >12 years duration must have documented evidence that a surveillance colonoscopy was performed within 12 months prior to initial screening (may be performed during Screening if not performed in previous 12 months).
- Has a family history of colorectal cancer, personal history of increased colorectal cancer risk, age >50 years, or other known risk factor must be up-to-date on colorectal cancer surveillance (may be performed during Screening).
Has demonstrated an inadequate response to, loss of response to, or intolerance of at least 1 of the following agents as defined below:
- Corticosteroids.
- Immunomodulators.
- Tumor necrosis factor-alpha (TNF-α) antagonists.
Exclusion Criteria:
- Has evidence of abdominal abscess at the initial Screening Visit.
- Has had extensive colonic resection, subtotal or total colectomy.
- Has a history of >3 small bowel resections or diagnosis of short bowel syndrome.
- Has had ileostomy, colostomy, known fixed symptomatic stenosis of the intestine, or evidence of fixed stenosis, or small bowel stenosis with prestenotic dilation.
- Has had previous exposure to approved or investigational anti-integrins (e.g., natalizumab, efalizumab, etrolizumab, or AMG-181), or MAdCAM-1 antagonists, or rituximab.
- Has used topical (rectal) treatment with 5-ASA, corticosteroid enemas/suppositories or traditional Chinese medications for CD treatment within 2 weeks of the administration of the first dose of study drug.
- Requires currently or is anticipated to require surgical intervention for CD during the study.
- Has a history or evidence of adenomatous colonic polyps that have not been removed.
- Has a history or evidence of colonic mucosal dysplasia including low or high-grade dysplasia, as well as indeterminate for dysplasia.
- Has a suspected or confirmed diagnosis of ulcerative colitis, indeterminate colitis, ischemic colitis, and radiation colitis.
- Has evidence of treatment for C.difficile infection or other intestinal pathogen with 28 days prior to first dose of study drug.
- Has chronic hepatitis B virus (HBV) infection or chronic hepatitis C virus (HCV) infection.
- Has active or latent tuberculosis.
- Has any identified congenital or acquired immunodeficiency (e.g., common variable immunodeficiency, human immunodeficiency virus [HIV] infection, organ transplantation).
- Has any history of malignancy, except for the following: (a) adequately-treated nonmetastatic basal cell skin cancer; (b) squamous cell skin cancer that has been adequately treated and that has not recurred for at least 1 year prior to randomization; and (c) history of cervical carcinoma in situ that has been adequately treated and that has not recurred for at least 3 years prior to randomization. Participants with remote history of malignancy (e.g., >10 years since completion of curative therapy without recurrence) will be considered based on the nature of the malignancy and the therapy received and must be discussed with the sponsor on a case-by-case basis prior to randomization.
- Has a history of any major neurological disorders, including stroke, multiple sclerosis, brain tumor, or neurodegenerative disease.
- Has a positive progressive multifocal leukoencephalopathy (PML) subjective symptom checklist at Screening or prior to the administration of the first dose of study drug at Week 0.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Induction Phase: Placebo
Placebo, IV, infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
|
Vedolizumab IV infusion
|
Experimental: Induction Phase: Vedolizumab 300 mg
Vedolizumab 300 milligram (mg), IV infusion, once at Weeks 0, 2, and 6 in the Induction Phase.
|
Vedolizumab placebo-matching
|
Placebo Comparator: Maintenance Phase: Induction Placebo to Placebo Q4W
Participants who received placebo in the Induction Phase and achieved clinical response at Week 10 continued to receive placebo in the Maintenance Phase.
Vedolizumab placebo-matching, IV infusion, once every 4 weeks (Q4W), from Week 14 to Week 58.
|
Vedolizumab IV infusion
Vedolizumab placebo-matching
|
Experimental: Maintenance Phase: Induction Placebo to Vedolizumab 300 mg Q4W
Participants who received placebo in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase.
Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
|
Vedolizumab IV infusion
|
Experimental: Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q8W
Participants who received vedolizumab in the Induction Phase and achieved clinical response at Week 10 continued to receive vedolizumab in the Maintenance Phase.
Vedolizumab 300 mg, IV infusion, once every 8 weeks (Q8W), at Weeks 14, 22, 30, 38, 46 and 54 and vedolizumab placebo-matching, IV infusion, Q8W, at Weeks 18, 26, 34, 42, 50 and 58 to maintain double-blind.
|
Vedolizumab placebo-matching
|
Experimental: Maintenance Phase: Induction Vedolizumab 300 mg to Vedolizumab 300 mg Q4W
Participants who received vedolizumab in the Induction Phase and did not achieve clinical response at Week 10 received vedolizumab in the Maintenance Phase.
Vedolizumab 300 mg, IV infusion, Q4W, from Week 14 to Week 58.
|
Vedolizumab IV infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Enhanced Clinical Response in the Induction Phase at Week 10
Time Frame: Week 10
|
Enhanced clinical response was defined as ≥100-point decrease from Baseline in the Crohn's Disease Activity Index (CDAI) score at Week 10.
A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers.
CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight).
CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity.
|
Week 10
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Clinical Remission in the Induction Phase at Week 10
Time Frame: Week 10
|
Clinical remission was defined as CDAI score of ≤150 points at Week 10.
A CDAI is a multi-item instrument which measures severity of active Crohn's Disease monitored over 7 days includes participant reported symptoms, physician-assessed signs, and laboratory markers.
CDAI score is equal to sum of weighted scores for subjective items (number of liquid/soft stools, degree of abdominal pain, general well-being); and objective items (use of anti-diarrhoeal medication, abdominal mass, haematocrit, presence of extraintestinal manifestation, body weight).
CDAI scores range approximately from 0 to 600, higher scores indicating greater disease activity
|
Week 10
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Vedolizumab-3034
- U1111-1195-3932 (Other Identifier: World Health Organization)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn's Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Massachusetts General HospitalAmerican College of GastroenterologyNot yet recruitingInflammatory Bowel Diseases | Crohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's EsophagitisUnited States
-
Richard Burt, MDTerminatedCROHN'S DISEASEUnited States
-
Agomab Spain S.L.RecruitingFibrostenotic Crohn's DiseaseUnited States, Italy, Poland, Spain, Denmark, Austria, Canada, Germany
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Belgium, Canada, Czechia, Denmark, France, Germany, Hungary, Israel, Italy, Netherlands, New Zealand, Norway, Poland, Romania, Slovakia, Spain, United Kingdom
-
AbbVieActive, not recruitingCrohn's Disease (CD)United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, China, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Romania, Russian Federation, Slo... and more
-
University Hospital, LilleMinistry of Health, FranceTerminatedCrohn's Disease AggravatedFrance
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
Weill Medical College of Cornell UniversityThe Kenneth Rainin FoundationRecruitingCrohn's Disease (CD)United States
Clinical Trials on Vedolizumab IV
-
TakedaRecruitingCrohn's DiseaseChina
-
TakedaCompletedCrohn Disease | Ulcerative ColitisIndia
-
TakedaCompletedColitis, UlcerativeUnited States, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Spain, Croatia, Israel, Serbia, Bulgaria, Canada, Italy, Poland, Ukraine, Hungary, Belgium, Czechia, Turkey, Germany, Japan, Estonia, Mexico, Romania and more
-
TakedaCompleted
-
TakedaCompletedColitis, UlcerativeUnited States, Canada
-
TakedaCompletedCrohn's DiseaseBelgium, Israel, Korea, Republic of, Netherlands, Australia, Denmark, Russian Federation, Hungary, Serbia, Bulgaria, Canada, Germany, Italy, Poland, Slovakia, Czechia, Mexico, Romania, Brazil, Estonia, United States, Bosnia and Herzegovina and more
-
TakedaRecruitingModerately to Severely Active Ulcerative ColitisChina
-
TakedaNot yet recruitingCrohn's Disease | Ulcerative Colitis
-
TakedaRecruitingCrohn's Disease (CD)United States, Australia, Israel, Belgium, Hungary, Canada, China, Croatia, Czechia, Greece, Italy, Japan, Korea, Republic of, Poland, United Kingdom, Lithuania, Slovakia, Spain
-
TakedaRecruitingCrohn's Disease | Ulcerative ColitisBelgium, Australia, Israel, United States, Hungary, Korea, Republic of, China, Canada, Croatia, Italy, Poland, Slovakia, United Kingdom, Japan, Greece